key: cord-0968696-hxawtzt3 authors: Jungbauer, Christof; Weseslindtner, Lukas; Weidner, Lisa; Gänsdorfer, Simon; Farcet, Maria R.; Gschaider‐Reichhart, Eva; Kreil, Thomas R. title: Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations date: 2020-09-25 journal: Transfusion DOI: 10.1111/trf.16119 sha: 980c3b3aebb03255883b22142db2f9855d0a64d4 doc_id: 968696 cord_uid: hxawtzt3 BACKGROUND: Transfusion of SARS‐CoV‐2 convalescent plasma is a promising treatment for severe COVID‐19 cases, with success of the intervention based on neutralizing antibody content. Measurement by serological correlates without biocontainment needs, and an understanding of donor characteristics that may allow for targeting of more potent donors would greatly facilitate effective collection. STUDY DESIGN AND METHODS: One hundred convalescent plasma units were characterized for functionally active SARS‐CoV‐2 neutralizing antibodies, as well as for SARS‐CoV‐2 binding antibodies, with the intention to establish a correlation between the functionally more relevant neutralization assay and the more accessible ELISA. Donor demographics such as COVID‐19 disease severity, age and sex were correlated with antibody titers. RESULTS: A mean neutralization titer 50% of 1:230 (range < 1:8 – 1:1765) was seen for the 100 convalescent plasma units, with highly significant (p < 0.0001), yet quantitatively limited (R(2) = 0.2830) correlation with results of the ELISA. Exclusion of units with particularly high titers (>1:500) from analysis improved correlation (R(2) = 0.5386). A tendency of higher titer plasma units from donors with increased disease severity, advanced age and of male sex was seen, yet the functional relevance of this difference is questionable. CONCLUSION: The ELISA‐based correlation to neutralization titer enabled a threshold proposal that could be used to eliminate lower titer units from the clinical supply for COVID‐19 treatment. Disease severity may be associated with the development of higher titers of neutralizing antibodies, although larger case numbers will be needed for additional confirmation. This article is protected by copyright. All rights reserved. The transfusion of convalescent plasma (CP) for the treatment of infectious diseases has been in medical use for more than 100 years and was found worthy of the first Nobel Prize in Medicine, awarded to Emil von Behring in 1901. Based on some earlier successes of CP therapy with the other two zoonotic coronaviruses that have caused large numbers of severe respiratory infections in humans during the last two decades, i.e. Severe acute respiratory syndrome -Coronavirus (SARS-CoV) and Middle East respiratory syndrome -Coronavirus (MERS-CoV) 1,2 , its use was quickly initiated after the emergence of the now pandemic SARS-CoV-2 in late 2019. [3] [4] [5] For the identification of potential SARS-CoV-2 CP donors, different analytical approaches are possible, and some have been suggested. 6, 7 These include detection of the virus by nucleic acid testing during acute infection, and after convalescence the detection of virus binding antibodies by enzyme-linked immunosorbent assay (ELISA), lateral flow or Western blot assays, or the detection of functional antibodies by virus microneutralization test (MNT). 8 Only a MNT provides for a functional correlate of antiviral efficacy and this assay is therefore still considered as 'gold standard' in serological testing, yet testing needs to be conducted under level 3 biosafety containment restrictions (BSL3), requires a few days to generate results and is more complex to perform. It would thus greatly facilitate testing for SARS-CoV-2 antibodies in potential plasma donors and their donations, if a more simple and easily scalable binding assay can be correlated against functional antibody activity as determined by MNT. In addition, CP collections might become more effective if donor characteristics were understood to correlate with higher functional antibody activity, such as e.g. disease severity, days between disease onset and plasma collection, or age and sex of donors. This article is protected by copyright. All rights reserved. The Austrian Red Cross Blood Service for Vienna, Lower Austria and Burgenland initiated the collection of virus-inactivated CP by plasmapheresis at the Vienna Blood Centre. Here, we report the characterization of the first 100 CP units collected for functionally active neutralizing antibodies by MNT as well as by a binding antibody assay. The first 100 CP units collected by the Austrian Red Cross Blood Service for Vienna, Lower Austria and Burgenland were tested for functionally active neutralizing antibodies by MNT. While the absolute numbers generated by any such assay need to await availability of international reference standards before any meaningful comparison becomes possible, on average the CP units had high neutralizing antibody titer, with a mean microneutralization titer 50% (NT 50 ) of approx. 1:230 ( Figure 1A -NT 50 histogram, median 1:100, 25% percentile 1:54, 75% percentile 1:231, range < 1:8 -1:1765). Somewhat surprisingly for individuals who had successfully recovered from PCR-confirmed SARS-CoV-2 infection, neutralizing antibodies were undetectable in one plasma unit, and for a total of six units (6%) the NT 50 s were below 1:23, i.e. INV log 2 NT 50 4.5 ( Figure 1A) . A binding antibody assay was also performed on these CP units, with the intention to establish a correlation between the functionally more relevant MNT and the more accessible ELISA, as well as an ELISA threshold to allow for the elimination of sub-potent units and the qualification of CP units for transfusion. For the totality of the samples for which valid results from both assays were available (N = 83), the correlation between results from the MNT and the ELISA was highly significant (p < 0.0001), yet quantitatively limited (R 2 = 0.2830) This article is protected by copyright. All rights reserved. ( Figure 1B) . With the intention of using the ELISA primarily for establishing a lower threshold for CP units to issue them for treatment of COVID-19 cases, the analysis was repeated excluding particularly high NT 50 titers (>1:500, N = 12 / 14.5%), which improved the correlation (R 2 = 0.5386; Figure 1B) For the targeted collection of high antibody titer CP units it would be helpful to understand donor characteristics that might correlate with higher antibody potency, for example it has been suggested that increasing disease severity may result in the development of higher antibody titers. 9 Of the 100 plasma donors, 90 were classified into WHO disease severity scores of 1 and 2, 10 with an average NT 50 of 1:208, versus only 6 donors in disease severity scores of 3 to 6, who had a mean NT 50 antibody titer of 1:696. While these results may seem to support the notion of higher titers with increased disease severity, the numbers of CP donors in higher WHO scores in this study are too low to determine significance. For CP donor age (Figure 2A) , the NT 50 s were significantly correlated (p = 0.0019), yet with little predictive value (R 2 = 0.09466) and targeting advance age donors for CP collection may therefore not be very effective. On average, the CP collected from male donors (N = 61) had a significantly higher mean NT 50 than from female donors (N=38), yet whether the mean titer difference of 1:220 has any functional relevance is questionable ( Figure 2B ). This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Use of convalescent plasma therapy in SARS patients in Hong Kong Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Convalescent plasma treatment of severe COVID-19: A matched control study European Commission, Directorate-General for Health and Food Safety. An EU programme of COVID-19 convalescent plasma collection and transfusion Investigational COVID-19 Convalescent Plasma; Guidance for Industry Serology assays to manage COVID-19 Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 World Health Organization, Ordinal Scale for Clinical Improvement. R&D Blueprint and COVID-19. WHO reference number WHO/WHO/R&D Blueprint (CoVID) This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.